New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
- Authors: Dragomiretskaya N.A.1, Tarzimanova A.I.1, Kucherova J.S.1, Podzolkov V.I.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 93, No 9 (2021)
- Pages: 1132-1137
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/82988
- DOI: https://doi.org/10.26442/00403660.2021.09.201016
- ID: 82988
Cite item
Full Text
Abstract
Mineralocorticoid receptor antagonists have been successfully used for many years to treat patients with primary hyperaldosteronism, refractory arterial hypertension and chronic heart failure. The increased interest in this drug in recent years is due to new information about its antifibrotic and antiproliferative effects, both cardiac and extracardiac. The article also discusses the possibility of using spironolactone in patients with the new coronavirus infection SARS-CoV-2 (COVID-19).
Full Text
##article.viewOnOriginalSite##About the authors
Natalia A. Dragomiretskaya
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: dragomiretskaya_natalia@mail.ru
ORCID iD: 0000-0002-6531-6255
канд. мед. наук, доц. каф. факультетской терапии №2 лечебного фак-та
Russian Federation, MoscowAida I. Tarzimanova
Sechenov First Moscow State Medical University (Sechenov University)
Email: dragomiretskaya_natalia@mail.ru
ORCID iD: 0000-0001-9536-8307
д-р мед. наук, проф. каф. факультетской терапии №2 лечебного фак-та
Russian Federation, MoscowJulia S. Kucherova
Sechenov First Moscow State Medical University (Sechenov University)
Email: dragomiretskaya_natalia@mail.ru
ORCID iD: 0000-0003-4701-9473
студентка
Russian Federation, MoscowValery I. Podzolkov
Sechenov First Moscow State Medical University (Sechenov University)
Email: dragomiretskaya_natalia@mail.ru
ORCID iD: 0000-0002-0758-5609
д-р мед. наук, проф., зав. каф. факультетской терапии №2 лечебного фак-та, дир. факультетской терапевтической клиники
Russian Federation, MoscowReferences
- Kagawa CM, Sturtevant FM, Van Arman CG. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharmacol Exp Ther. 1959;126(2):123-30.
- Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129-38. doi: 10.2147/IBPC.S13783
- Подзолков В.И., Булатов В.А. Ренин-ангиотензин-альдостероновая система как краеугольный камень сердечно-сосудистого и почечного континуума. Органопротективные свойства антагонистов рецепторов к ангиотензину II. Атмосфера. Новости кардиологии. 2005;3:20-5 [Podzolkov VI, Bulatov VA. The renin-angiotensin-aldosterone system as a cornerstone of the cardiovascular and renal continuum. Organoprotective properties of angiotensin II receptor antagonists. Atmosphere. Cardiology News. 2005;3:20-5 (in Russian)].
- Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis. 2016;10(3):162-71.
- Kim SK, McCurley AT, DuPont JJ, et al. Smooth Muscle Cell-Mineralocorticoid Receptor as a Mediator of Cardiovascular Stiffness With Aging. Hypertension. 2018;71(4):609-21. doi: 10.1161/HYPERTENSIONAHA.117.10437
- Food and drug administration center for drug evaluation and research cardiovascular and renal drugs: advisory committee (CRDAC) meeting. Virtual Meeting Wednesday, December 16, 2020 9:00 a.m. to 1:37 p.m. Available at: https://www.fda.gov/media/146717/download. Accessed: 21.08.2021.
- Подзолков В.И., Драгомирецкая Н.А. Антагонисты альдостерона. Современные представления о механизмах действия и эффектах спиронолактона. Рациональная фармакотерапия в кардиологии. 2017;13(2):263-9 [Podzolkov VI, Dragomiretskaya NA. Aldosterone antagonists. Modern views on the mechanism of action and effects of spironolactone. Rational Pharmacotherapy in Cardiology. 2017;13(2):263-9 (in Russian)]. doi: 10.20996/1819-6446-2017-13-2-263-269
- Liu B, Zhang TN, Knight JK, Goodwin JE. The Glucocorticoid Receptor in Cardiovascular Health and Disease. Cells. 2019;8(10):1227. doi: 10.3390/cells8101227
- Kotfis K, Lechowicz K, Drożdżal S, et al. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. Pharmaceuticals (Basel). 2021;14(1):71. doi: 10.3390/ph14010071
- Hermidorff MM, de Assis LV, Isoldi MC. Genomic and rapid effects of aldosterone: what we know and do not know thus far. Heart Fail Rev. 2017;22(1):65-89. doi: 10.1007/s10741-016-9591-2
- Chen X, Ge W, Dong T, et al. Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats. Life Sci. 2019;224:177-86. doi: 10.1016/j.lfs.2019.01.017
- Funder JW. Spironolactone in cardiovascular disease: an expanding universe? F1000Res. 2017;6:1738. doi: 10.12688/f1000research.11887.1
- Kenchaiah S, Pfeffer MA. Cardiac remodeling in systemic hypertension. Med Clin North Am. 2004;88(1):115-30. doi: 10.1016/s0025-7125(03)00168-8
- Gouli A, Kaltsas G, Tzonou A, et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest. 2011;41(11):1227-36. doi: 10.1111/j.1365-2362.2011.02531.x
- Markou A, Pappa T, Kaltsas G, et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013;98(4):1409-16. doi: 10.1210/jc.2012-3353
- Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. doi: 10.1016/j.jacc.2005.01.015
- Savard S, Amar L, Plouin PF, et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331-6. doi: 10.1161/HYPERTENSIONAHA.113.01060
- Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4
- Yan Y, Wang C, Lu Y, et al. Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma. J Physiol Biochem. 2018;74(1):17-24. doi: 10.1007/s13105-017-0600-2
- Ori Y, Chagnac A, Korzets A, et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant. 2013;28(7):1787-93. doi: 10.1093/ndt/gfs587
- Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. doi: 10.1210/jc.2015-4061
- ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-104. doi: 10.1093/eurheartj/ehy339
- Williams B, MacDonald TM, Morant SV, et al. British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464-75. doi: 10.1016/S2213-8587(18)30071-8
- Sinnott SJ, Tomlinson LA, Root AA, et al. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(3):228-38. doi: 10.1177/2047487316675194
- Zhao D, Liu H, Dong P, et al. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol. 2017;233:113-7. doi: 10.1016/j.ijcard.2016.12.158
- Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES) Rales Investigators. Circulation. 2000;102:2700-6. doi: 10.1161/01.cir.102.22.2700
- Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158 [Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158 (in Russian)]. doi: 10.18087/cardio.2475
- Solomon SD, Claggett B, Lewis EF, et al. TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-62. doi: 10.1093/eurheartj/ehv464
- Li S, Zhang X, Dong M, et al. Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(35):e11942. doi: 10.1097/MD.0000000000011942
- Cohen JB, Schrauben SJ, Zhao L, et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail. 2020;8(3):172-84. doi: 10.1016/j.jchf.2019.09.009
- Ravassa S, Trippel T, Bach D, et al. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail. 2018;20(9):1290-9. doi: 10.1002/ejhf.1194
- Cleland JGF, Ferreira JP, Mariottoni B, et al.; HOMAGE Trial Committees and Investigators. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021;42(6):684-96. doi: 10.1093/eurheartj/ehaa758
- Haenel J. The effect of aldactone on advanced respiratory insufficiency (respiratory acidosis) in chronic cor pulmonale. Munch Med Wochenschr. 1963;105:2179-85 (in German).
- Lieber GB, Fernandez X, Mingo GG, et al. Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models. Eur J Pharmacol. 2013;718(1-3):290-8. doi: 10.1016/j.ejphar.2013.08.019
- Zhou H, Xi D, Liu J, et al. Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats. Drug Des Devel Ther. 2016;10:1581-8. doi: 10.2147/DDDT.S100095
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054-62. doi: 10.1016/S0140-6736(20)30566-3
- Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262. doi: 10.1016/j.metabol.2020.154262
- Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114. doi: 10.15252/embj.20105114
- Groß S, Jahn C, Cushman S, et al. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. J Mol Cell Cardiol. 2020;144:47-53. doi: 10.1016/j.yjmcc.2020.04.031
- Clinckemalie L, Spans L, Dubois V, et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013;27:2028-40. doi: 10.1210/me.2013-109
- Мареев В.Ю., Орлова Я.А., Плисюк А.Г., и др. Результаты открытого проспективного контролируемого сравнительного исследования по лечению новой коронавирусной инфекции (COVID-19): Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(11):4-15 [Mareev VYu, Orlova YaA, Plisyk AG, et al. Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT). Kardiologiia. 2020;60(11):4-15 (in Russian)]. doi: 10.18087/cardio.2020.11.n1440
- Cadegiani FA, Wambier CG, Goren A. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Front Med (Lausanne). 2020;7:453. doi: 10.3389/fmed.2020.00453
- Mackenzie IS, Morant SV, Wei L, et al. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol. 2017;83(3):653-63. doi: 10.1111/bcp.13152